HighTide Therapeutics is a globally integrated clinical-stage biopharmaceutical company focusing on the discovery and development of novel multifunctional therapies for metabolic and digestive diseases with significant unmet medical needs. The company’s lead drug candidate, HTD1801, is a first-in-class new molecular entity, currently in clinical development for the treatment of type 2 diabetes (T2DM), non-alcoholic steatohepatitis (NASH), severe hypertriglyceridemia (SHTG), and primary sclerosing cholangitis (PSC). HTD1801 has received Fast Track designation from the US FDA for both NASH and PSC, as well as Orphan Drug designation for PSC. In China, HTD1801 has been included in the National Major New Drug Innovation Program.
Mission：Focus on patient‑centric drug development to bring total and optimal benefits to patients
Vision: Become a leading and respected globally integrated biotech company
· Simplicity is the ultimate sophistication
· Mind and hand
· All for one and one for all, united we stand
· Resilient growth
· Think win/win